🇺🇸 FDA
Pipeline program

Praluent (Alirocumab)

R727-CL-1532

Approved small_molecule completed

Quick answer

Praluent (Alirocumab) for Hypercholesterolemia is a Approved program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Hypercholesterolemia
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials